COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
a Herbert Irving Comprehensive Cancer Center, Columbia University, New York, United States
b Alfred Health, Melbourne, Victoria, Australia
c Monash University, Melbourne, Victoria, Australia
d Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
e Loxo@Lilly, Indianapolis, United States
f Eli Lilly and Company, Indianapolis, United States
g Grupo Oncoclínicas, Rio de Janeiro, Brazil
Lido
911
Vezesque se leu este artigo
381
Total PDF
530
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 13 | 31 |
| 2025 5 | 33 | 9 | 42 |
| 2025 4 | 29 | 11 | 40 |
| 2025 3 | 48 | 7 | 55 |
| 2025 2 | 34 | 26 | 60 |
| 2025 1 | 31 | 31 | 62 |
| 2024 12 | 20 | 30 | 50 |
| 2024 11 | 28 | 21 | 49 |
| 2024 10 | 29 | 23 | 52 |
| 2024 9 | 34 | 19 | 53 |
| 2024 8 | 44 | 16 | 60 |
| 2024 7 | 30 | 21 | 51 |
| 2024 6 | 37 | 17 | 54 |
| 2024 5 | 28 | 32 | 60 |
| 2024 4 | 30 | 19 | 49 |
| 2024 3 | 20 | 13 | 33 |
| 2024 2 | 9 | 16 | 25 |
| 2024 1 | 4 | 2 | 6 |
| 2023 12 | 11 | 21 | 32 |
| 2023 11 | 9 | 27 | 36 |
| 2023 10 | 4 | 7 | 11 |
Mostrar tudo
